Efficacy and effects of Trastuzumab

Trastuzumab (Trastuzumab) is a targeted therapy drug used to treat HER2 (human epidermal growth factor receptor 2)-positive breast cancer and gastric/esophageal cancer. By binding to the HER2 receptor, it blocks signaling and inhibits the growth and division of tumor cells, thereby slowing or stopping tumor growth. Trastuzumab is an important targeted therapy drug with significant efficacy in the treatment of HER2-positive breast cancer and gastric/esophageal cancer.

Trastuzumab can be used for the treatment of early and late-stage breast cancerHER2-positive breast cancer. In patients with early-stage breast cancer, it can significantly reduce the risk of tumor recurrence and death. In patients with advanced breast cancer and gastric/esophageal cancer, it can also improve the survival time of patients. Trastuzumab can be used in combination with chemotherapy drugs to improve the efficacy of chemotherapy. This is because trastuzumab can increase the sensitivity of tumors to chemotherapy drugs and achieve better therapeutic effects through synergy. Trastuzumab can be used to treat early-stage and advanced HER2-positive breast cancer. The use of trastuzumab may reduce the risk of metastasis in patients with HER2-positive breast cancer. The drug blocks the process of tumor cell invasion and migration, thereby reducing metastasis to distant organs.

Trastuzumab is sold under the brand name Herceptin in China and has entered the scope of Class B medical insurance, but it may be limited to patients who meet the indications for this drug, such as patients with HER2-positive metastatic breast cancer and its adjuvant and neoadjuvant treatment or HER2-positive metastatic gastric cancer. The price is around 6,000 yuan. The original trastuzumab drug has also been launched overseas. The drug ingredients of domestic and foreign original drugs are basically the same. For specific prices and drug details, you can consult the medical consultant. There is currently no generic drug of trastuzumab on the market.